Immune-Related Polyneuropathy and Generalized Myoclonus Associated with Pembrolizumab in a Patient with Metastatic Melanoma: A Case Report and Literature Review
Main Article Content
Abstract
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their articles and grant the journal the right of first publication under the Creative Commons Attribution (CC BY) license, which allows others to share and adapt the work with proper attribution.
References
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022 [acesso 2024 maio 1]. Disponível em: https://www.inca.gov.br/publicacoes/livros/estimativa-2023-incidencia-de-cancer-no-brasil
Pestronk A. Neuromuscular Disease Center. St. Louis: Washington University School of Medicine; 1987-2024 [acesso 2024 maio 1]. Disponível em: https://neuromuscular.wustl.edu
McCormack SM, Hamad A. Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series. Cureus. 2023 Sep 6;15(9):e44799. doi: 10.7759/cureus.44799.
Albarrán V, Chamorro J, Rosero DI, Saavedra C, Soria A, Carrato A, et al. Neurologic Toxicity of Immune Checkpoint Inhi-bitors: A Review of Literature. Front Pharmacol. 2022 Feb 14;13:774170. doi: 10.3389/fphar.2022.774170.
Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory Myopathy and Axonal Neuro-pathy in a Patient With Melanoma Following Pembrolizumab Treatment. J Immunother. 2017 Jul/Aug;40(6):221-223. doi: 10.1097/CJI.0000000000000172.
Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017 Mar;73:1-8. doi: 10.1016/j.ejca.2016.12.001.
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184.
Gallagher A, Murphy M, McDermott R, Alexander M, O'Dowd S. Pembrolizumab-Induced Steroid-Responsive Myoclonus. Mov Disord Clin Pract. 2022 May 3;9(4):546-550. doi: 10.1002/mdc3.13453.
Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7:134. doi:10.1186/s40425-019-0617-x.
Dinoto A, Trentinaglia M, Carta S, Mantovani E, Ferrari S, Tamburin S, et al. Autoimmune Movement Disorders Complica-ting Treatment with Immune Checkpoint Inhibitors. Mov Disord Clin Pract. 2024;11(5):543-549. doi:10.1002/mdc3.14003.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440.